THEMISMED
vs
B
BSE Sensex 30
THEMISMED
Over the past 12 months, THEMISMED has underperformed BSE Sensex 30, delivering a return of -37% compared to the BSE Sensex 30's 1% drop.
Stocks Performance
THEMISMED vs BSE Sensex 30
Performance Gap
THEMISMED vs BSE Sensex 30
Performance By Year
THEMISMED vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Themis Medicare Ltd
Glance View
Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. The firm is focused on the formulation and active pharmaceutical ingredients (API) activity. Its product category includes star products, differential products, and APIs. Its star products include OD-LM (Levocetrizine 5 mg + Montelukast 10 mg), Medzol (Midazolam hydrochloride 1 ml, 5ml and 10 ml), Cisatra (Cisatracurium 2 mg/ml), and Aquadol (Diclofenac sodium 75mg/ml). Its differential products include Enterofizz-EL (Bacillus clausii + Electrolytes) and Etojet (Etoricoxib 90mg/ml). Its APIs products include Simvastatin, Ketamine Hcl, and Isosorbide Di Methyl Ether (THEMISOL).The Company’s manufacturing locations in India are situated at Vapi, Haridwar and Hyderabad. The firm markets in over 44 countries. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
